{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:12:37Z","timestamp":1763035957721,"version":"build-2065373602"},"reference-count":28,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2004,10,12]],"date-time":"2004-10-12T00:00:00Z","timestamp":1097539200000},"content-version":"vor","delay-in-days":4302,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[1993,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Buspirone, an azospirone compound, is a nonsedative anxiolytic that has achieved wide usage since its introduction in 1987. Although relatively free of side\u2010effects, there have been several instances of dyskinesia and dystonia associated with the use of buspirone. We report two patients with persistent movement disorders that developed after prolonged treatment with the drug. One patient developed a lasting problem of cervical\u2013cranial dystonia and tremors after treatment with buspirone at a dosage of 40 mg\/day for several weeks. Another, receiving 30 mg\/day for 6 weeks, experinced an exacerbation of preexisting spasmodic torticollis and tardive dyskinesia as well as the onset of involuntary phonations. As shown by these and other examples, buspirone poses the risk for inducing or exacerbating several types of movement disorders.<\/jats:p>","DOI":"10.1002\/mds.870080313","type":"journal-article","created":{"date-parts":[[2004,12,31]],"date-time":"2004-12-31T10:07:02Z","timestamp":1104487622000},"page":"331-334","source":"Crossref","is-referenced-by-count":33,"title":["Persistent movement disorders induced by buspirone"],"prefix":"10.1002","volume":"8","author":[{"given":"Peter A.","family":"Lewitt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Walters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne","family":"Hening","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"McHale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,10,12]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1523\/JNEUROSCI.03-04-00733.1983","article-title":"Dopamine receptor antagonism by the novel anxiolytic drug, buspirone","volume":"3","author":"McMillen BA","year":"1983","journal-title":"J Neurosci"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198632020-00002"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(86)90327-X"},{"key":"e_1_2_1_5_2","first-page":"111","article-title":"Movement disorders and new azapirone anxiolytic drugs","volume":"3","author":"Jann MW","year":"1990","journal-title":"J Amer Board Fam Prac"},{"key":"e_1_2_1_6_2","first-page":"322","article-title":"Oral dyskinesia associated with buspirone use in an elderly woman","volume":"49","author":"Strauss A.","year":"1988","journal-title":"J Clin Psychiatr"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-198808000-00026"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.40.12.1904"},{"key":"e_1_2_1_9_2","first-page":"242","article-title":"Acute generalized myoclonus following buspirone administration","volume":"49","author":"Ritchie EC","year":"1988","journal-title":"J Clin Psychiatr"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198612000-00007"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.54.4.376-a"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198608000-00004"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-198904000-00026"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)92070-9"},{"key":"e_1_2_1_15_2","first-page":"701","article-title":"MJ 9022: correlation between neuroleptic potential and stereotypy","volume":"18","author":"Sathanathan GL","year":"1975","journal-title":"Curr Therap Res"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-198902000-00021"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(82)90265-5"},{"key":"e_1_2_1_18_2","first-page":"308","article-title":"Preclinical pharmacology of buspirone hydrochloride","volume":"4","author":"Skolnick P","year":"1984","journal-title":"Pharmacol"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(83)90386-7"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1985.tb08940.x"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.430040111"},{"key":"e_1_2_1_22_2","first-page":"127","article-title":"The effect of MJ\u20109022\u20101 on striatal DOPAC and apomorphine\u2010induced stereotyped behaviour in rats","volume":"4","author":"Stanley M","year":"1979","journal-title":"Res Comm Psychol Psychiatr Behav"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(83)90627-5"},{"key":"e_1_2_1_24_2","doi-asserted-by":"crossref","unstructured":"EisonAS TempleDL. Buspirone: review of its pharmacogy and current perspectives on its method of action.Am J Med1986; (suppl 3B):1\u20139.","DOI":"10.1016\/0002-9343(86)90325-6"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01248997"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01259341"},{"key":"e_1_2_1_27_2","first-page":"11","article-title":"Pharmacology and neurochemistry of buspirone","volume":"43","author":"Riblet LA","year":"1982","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00431929"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.148.5.661"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.870080313","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.870080313","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:28:47Z","timestamp":1760963327000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.870080313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993,1]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1993,1]]}},"alternative-id":["10.1002\/mds.870080313"],"URL":"https:\/\/doi.org\/10.1002\/mds.870080313","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"type":"print","value":"0885-3185"},{"type":"electronic","value":"1531-8257"}],"subject":[],"published":{"date-parts":[[1993,1]]}}}